- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02570646
QuitAdvisorDDS: A Point-of-Care Tobacco Cessation Tool for Dental Settings (QA-DDS)
April 1, 2019 updated by: Jamie Studts
Using a single-arm trial design, this study will examine the feasibility and acceptability of evaluating QuitAdvisorDDS, a clinical decision support software application designed to facilitate implementation of evidence-based tobacco treatment interventions into the dental setting.
The study will examine the feasibility and acceptability of evaluating the impact of the QuitAdvisorDDS tool on patient outcomes related to tobacco use and cessation attempts as well as provider knowledge, attitudes, and practices regarding tobacco treatment.
Practitioners (dentists and hygienists) will complete surveys at baseline and follow-up, while patients will complete surveys at baseline and 1-month follow-up.
An embedded substudy will also evaluate the feasibility and acceptability of collecting biospecimens (saliva) to serve as biochemical verification of smoking status.
Study Overview
Study Type
Interventional
Enrollment (Actual)
248
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536-0086
- University of Kentucky
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Receives dental care from a participating practitioner;
- Is age 18 or older;
- Self-reports tobacco use within the past month;
- Willing to comply with all study procedures and be available for the duration of the study;
- Willing to provide verbal informed consent;
- Has access to a telephone, and agrees to receive text messages, emails, or telephone calls related to the study. (The patient's preferred method of contact will be ascertained).
- Willing to be contacted on a regular basis by each of these entities: the practice;Regional Coordinators (RC) and/or University of Kentucky (UK) researchers; and
- Willing to provide contact information of one person living at a different address who will know the patient's whereabouts in the event the patient cannot be reached.
Exclusion Criteria:
- Psychiatric disability or mental illness judged by the practitioner to be clinically significant so as to preclude informed consent or compliance with procedures of study visits.
- Cognitive impairment judged by the practitioner to be significant so as to preclude informed consent or compliance with procedures of study visits.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: QA-DDS
Patients will receive exposure to the QA-DDS tool from their dental care practitioner.
|
QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Patient Acceptability A: Rate of Patient Wanting Provider to Use QA-DDS
Time Frame: Immediately Post-Consultation up to 1 week
|
80% of participating patients must indicate that they would want their dental practitioner to continue to use QA-DDS.
|
Immediately Post-Consultation up to 1 week
|
Primary Patient Acceptability B: Rate of Patient Wanting to Use QA-DDS Patient Portal
Time Frame: 1-Month Follow-Up
|
80% of participating patients must indicate that they would want to continue to use the QA-DDS Patient Portal.
|
1-Month Follow-Up
|
Primary Patient Feasibility A: Rate of Patient Completion of 1-Month Follow-Up Survey
Time Frame: 1-Month Follow-Up
|
80% of the enrolled dental care patients must complete the 1-month follow-up survey with the 7-day point prevalence measure of self-reported smoking status.
|
1-Month Follow-Up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Patient Acceptability A: Average QA-DDS Satisfaction Ratings Among Patients on 0-10 Scale
Time Frame: Immediately Post-Consultation up to 1 week
|
Average QA-DDS satisfaction ratings among enrolled dental patients must be 7 or greater on a 0-10 scale.
|
Immediately Post-Consultation up to 1 week
|
Secondary Patient Feasibility A: Rate of Patient Accrual by Study Practices
Time Frame: 4-Month Follow-Up
|
75% of the study practices must recruit 10 eligible dental patients within a 4-month recruitment phase
|
4-Month Follow-Up
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tertiary Patient Acceptability A1: Number of Patients Who Visit QA-DDS Patient Portal
Time Frame: 1-Month Follow-Up
|
To evaluate the acceptability of the QA-DDS Patient Portal among enrolled dental patients, the percentage of enrolled patients who make at least one visit to the Patient Portal will be monitored
|
1-Month Follow-Up
|
Tertiary Patient Acceptability A2: Number of Visits to QA-DDS Patient Portal Per Patient
Time Frame: 1-Month Follow-Up
|
To evaluate the acceptability of the QA-DDS Patient Portal among enrolled dental patients, the number of visits to the Patient Portal per patient will be monitored
|
1-Month Follow-Up
|
Tertiary Patient Acceptability B: Rate of QA-DDS Text Messaging Support Service Use as Measured by Number of Patient Subscriptions
Time Frame: 1-Month Follow-Up
|
To evaluate the acceptability of the QA-DDS Text Messaging Support Service, the percentage of enrolled patients who subscribe to the Text Messaging Support Service will be monitored.
|
1-Month Follow-Up
|
Tertiary Patient Feasibility A: Rate of Missing Data for Tobacco Use Among Patients
Time Frame: 1-Month Follow-Up
|
Self-reported measures of tobacco use and history at the follow-up assessment must have less than 10% missing data among responding dental patients.
|
1-Month Follow-Up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jamie L Studts, PhD, Associate Professor, University of Kentucky College of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2015
Primary Completion (Actual)
November 1, 2016
Study Completion (Actual)
November 1, 2016
Study Registration Dates
First Submitted
October 3, 2015
First Submitted That Met QC Criteria
October 5, 2015
First Posted (Estimate)
October 7, 2015
Study Record Updates
Last Update Posted (Actual)
April 3, 2019
Last Update Submitted That Met QC Criteria
April 1, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- 10-155-E
- R44DE021327 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use
-
Loma Linda UniversityUniversity of California, San Francisco; Riverside University Health System...RecruitingTobacco Use | Tobacco Use Cessation | Tobacco Use in ChildbirthUnited States
-
University of VirginiaVirginia Foundation for Healthy YouthActive, not recruitingTobacco Use | Electronic Cigarette Use | Tobacco Use CessationUnited States
-
Vanderbilt University Medical CenterCompletedTobacco Use | Tobacco Use Cessation
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Altria Client Services LLCICON Clinical ResearchNot yet recruitingTobacco Use | Tobacco SmokingUnited States
-
British American Tobacco (Investments) LimitedCompletedTobacco Use | Tobacco SmokingUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
Clinical Trials on QA-DDS
-
Tzu Chi University of Science and TechnologyEnrolling by invitation
-
US Department of Veterans AffairsCompleted
-
AllerganOculex PharmaceuticalsCompletedDiabetes | Diabetic Retinopathy | Macular Edema | Uveitis, Posterior | Retinal DiseaseUnited States
-
Lviv National Medical UniversityCompleted
-
Hadassah Medical OrganizationUnknownIrreversible Pulpitis | Endodontic Treatment | Infected Pulp | Health PulpIsrael
-
AllerganCompletedPatients Who Participated in an Intravitreal Brimo PS DDS® StudyFrance, United Kingdom, Korea, Republic of, Czech Republic, Australia, Israel, India, Portugal, Germany, United States, Italy, Philippines
-
Hebrew SeniorLifeNational Institute of Nursing Research (NINR)Completed
-
PfizerJANSSEN Alzheimer Immunotherapy Research & Development, LLCCompleted
-
PfizerJANSSEN Alzheimer Immunotherapy Research & Development, LLCCompletedAlzheimer DiseaseJapan
-
Azienda Sanitaria Locale CN2 Alba-BraUniversity of Eastern Piedmont; Eclectica Sas di Beccaria Franca, Ermacora...CompletedMajor Risk Factors for Noncommunicable DiseasesItaly